from VideoGoogle Website
Tell everyone you know that the cure for AIDS is U.S. patent #5,676,977, and demand from your government officials that it begin clinical trials and widespread implementation immediately.
from USPatentAndTradeMarkOffice Website
The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag4 O4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans.
A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM.
When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic.
However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function.
Related U.S. Patent Documents
U.S. Patent Documents
Parent Case Text
BACKGROUND OF THE
Furthermore, said devices are capable of
killing pathogens and purging the bloodstream of immune suppressing
moieties (ISM) whether or not created by the AIDS virus (HIV); so as
to restore the immune system.
3 of said patent discloses that 18 PPM of said crystal devices could
totally suppress the AIDS virus (page 6, line 5). Subsequent to the
filing of the aforementioned patent, further testing revealed
complete 100% destruction of the AIDS virus in vitro at 20 PPM, and
the fact that said devices were harmless when ingested and inhaled,
The results of this test program
comprise Example 5 of U.S. Pat. No. 5,336,499. After success with
mice, the inventor was able to test the efficacy of said devices on
two select etiological groups of terminal AIDS patients in a clinic
in Tegucigalpa, Honduras, Central America.
Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients:
OBJECTS OF THE
Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag4 O4).
The crystal lattice of this molecule has a unique structure since it is a diamagnetic semiconducting crystal containing two mono and two trivalent silver ions, which in effect are capable of "firing" electrons under certain conditions which will destroy AIDS viruses, other pathogens and immune suppressing moieties (ISM), not only through the electrocution mode, but also by a binding process which occurs simultaneously with electron firing, namely, binding and chelation of divalent silver, i.e., the resulting product of the electron transfer redox that occur when the monovalent silver ions are oxidized and the trivalent ions are reduced in the crystal.
The binding/chelation effect occurs at active sites of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a single molecule of this crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a life support system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices.
Thus an optimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterate AIDS. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro.
concerning the structure of the crystal and its mechanism against
pathogens, the AIDS virus and ISM would analogously hold here, and
have already been further elucidated in said patent.
Accordingly, the tetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of this invention. Furthermore, three out of four wasting syndrome terminal patients and four out of the five candidiasis terminal patients were still alive in 1995 after a year and a half had elapsed from their initial injection.
that time all the AIDS patients had been released from the clinic
and allowed to return home.
It should, of
course, be recognized that the accompanying examples illustrate
preferred embodiments of the present invention and are not intended
as a means of defining the limits and scope of the present
factual presentations of the article were utilized and the
hypothesis of the authors was ignored. The facts presented in the
article related to the method of selecting AIDS patients based on
the five aforementioned etiological subgroups targeted by the CDC,
and the evidence presented, that there is AIDS without HIV as well
as with it so that an anti-viral agent in most instances will not
necessarily restore the immunity system.
The patients two weeks prior
to inoculation were removed from their AZT, AIDS therapy. Tetrasil
was administered at approximately 40 PPM of blood volume per patient
as a suspension in a proprietary buffer solution (pH=6.5), supplied
by Holipharm Corporation.
The H column, following CD 8, indicates whether hepatomegaly
occurred. This was an unfortunate consequence of the treatment which
resulted in enlarged livers in all patients except the second one.
Despite hepatomegaly, there was no interference with liver function.
The body temperature was invariably 38.5° C. (101.3° F.). This was indicative of restoration of the immune response of the body, since normally the body will destroy pathogens when the immune system is functional by raising the temperature. The patient who died; first responded favorably to Diflucan, which previously gave no response.
He was cured of his candidiasis, but unfortunately succumbed to his previous body damage.
All the other candidiasis syndrome people who previously did not respond to the indicated medications subsequently responded after the Tetrasil treatment. Further evidence of the recovery of the AIDS patients manifested itself 30 days after the initial injection when white blood cell counts were taken. They are shown in Table I under the WBC column, which gives the initial and final WBC.
All candidiasis patients
showed a dramatic increase in their white blood cell counts,
indicative of the restoration of their immunity systems.
The female patient, whose condition improved from poor and terminal to be among the living, showed a decrease in the WBC. However, she showed an increase in body temperature which was indicative of immune response. The test results indicate that one cannot rely on a single factor to indicate the demise of AIDS. The usual HIV marker CD 4 initial and final are irrelevant.
ISM suppression appears to be more critical than the destruction of HIV.
AIDS was suppressed, any permanent damage that had been done to the patients in the course of their succumbing to AIDS was not obviously cured or corrected by said crystal device treatment, rather said injury persisted and the patient was improved with respect to AIDS but still suffered from said permanent injury or impairment previously inflicted.
As this invention may be embodied in several forms without departing
from the spirit or essential characteristics thereof, the present
embodiments are therefore illustrative and not restrictive, since
the scope of the invention is defined by the appended claims rather
than by the description preceding them, and all changes that fall
within the metes and bounds of the claims or that form their
functional as well as conjointly cooperative equivalents, are
therefore intended to be embraced by these claims.